	US 12,221,622 B2
	Modified pluripotent cells
Sonja Schrepfer, Burlingame, CA (US); and Tobias Deuse, Burlingame, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on May 9, 2020, as Appl. No. 16/870,960.
Claims priority of provisional application 62/846,399, filed on May 10, 2019.
Claims priority of provisional application 62/855,499, filed on May 31, 2019.
Prior Publication US 2020/0354673 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0735 (2010.01); A61K 35/34 (2015.01); A61K 35/545 (2015.01); C12N 5/074 (2010.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01)

CPC C12N 5/0606 (2013.01) [A61K 35/34 (2013.01); C12N 5/0696 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); A61K 35/545 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2800/80 (2013.01)]

70 Claims

1. An isolated modified hypoimmunogenic human cell, comprising:

(a) a knock-out of one or more genes encoding an ABO blood group antigen, wherein the knock-out renders the hypoimmunogenic human cell ABO blood group-compatible with a recipient;

(b) a knock-out of one or more genes encoding a Rhesus factor (Rh) antigen, wherein the knock-out renders the hypoimmunogenic human cell Rh-compatible with the recipient; or

wherein the hypoimmunogenic human cell comprises:

(d) a knock-out of one or more Major Histocompatibility Antigen Class I (HLA-I) genes or one or more HLA-I associated genes, wherein the knock-out results in reduced or eliminated cell surface expression of an HLA-I complex as compared to an unmodified or wild-type human cell; and

(e) one or more CD47 transgenes that result in increased cell surface expression of CD47 as compared to an unmodified or wild-type human cell, wherein the one or more CD47 transgenes comprise a nucleic acid that encodes CD47 operably linked to a promoter.